Page last updated: 2024-10-27

fluorouracil and Esophageal Stenosis

fluorouracil has been researched along with Esophageal Stenosis in 16 studies

Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.

Esophageal Stenosis: A stricture of the ESOPHAGUS. Most are acquired but can be congenital.

Research Excerpts

ExcerptRelevanceReference
"Malignant esophageal stenosis is a common and severe complication of advanced esophageal cancer that can be a serious problem in the continuation of chemotherapy and other anticancer treatments."5.91Impact of preoperative docetaxel, cisplatin, and 5-fluorouracil (DCF) therapy on degree of malignant esophageal stenosis. ( Inaki, N; Kinoshita, J; Moriyama, H; Nakamura, K; Okamoto, K; Saito, H; Shimada, M; Tsuji, T; Yamaguchi, T, 2023)
"These studies demonstrate that the concurrent addition of modest dose cisplatin and infusional dose fluorouracil to radiation in the definitive, preoperative, and palliative settings contribute to high rates of durable dysphagia-free survival, with overall survival comparable to (and possibly better than) the chemoradiation arm of the recently reported Intergroup Study, but at the cost of less morbidity."5.08Combined modality therapy for esophageal carcinoma: preliminary results from a large Australasian multicenter study. ( Ackland, SP; Burmeister, BH; Denham, JW; Devitt, P; Gill, PG; Hamilton, CS; Jamieson, GG; Lamb, DS; O'Brien, M; Yeoh, E, 1995)
" Here, we report the case of a successfully treated patient with thoracic esophageal cancer who had esophageal perforation during docetaxel, cisplatin, and 5-fluorouracil chemotherapy."3.91Successful Stenting Followed by Surgery for Perforated Esophageal Cancer Due to Chemotherapy. ( Doki, Y; Kobayashi, T; Makino, T; Mori, M; Tanaka, K; Yamasaki, M, 2019)
"Esophageal stenosis was identified as a candidate stratification factor for randomized trials of unresectable LAESCC patients."2.84Esophageal stenosis and the Glasgow Prognostic Score as independent factors of poor prognosis for patients with locally advanced unresectable esophageal cancer treated with chemoradiotherapy (exploratory analysis of JCOG0303). ( Ando, N; Fukuda, H; Igaki, H; Ishikura, S; Katayama, H; Kato, H; Kato, K; Kawano, T; Kimura, Y; Kitagawa, Y; Kojima, T; Kosugi, S; Nakamura, K; Okabe, H; Okuno, T; Shinoda, M; Toh, Y; Tsubosa, Y; Wakabayashi, M, 2017)
"Esophageal stenosis was the only significant risk factor for esophageal fistula formation both in univariate (P = 0."2.82Risk Factors for Esophageal Fistula Associated With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Cancer: A Supplementary Analysis of JCOG0303. ( Fukuda, H; Honma, Y; Igaki, H; Kato, K; Kitagawa, Y; Mizusawa, J; Nakamura, K; Shinoda, M; Sudo, K; Tsubosa, Y; Tsushima, T, 2016)
"Malignant esophageal stenosis is a common and severe complication of advanced esophageal cancer that can be a serious problem in the continuation of chemotherapy and other anticancer treatments."1.91Impact of preoperative docetaxel, cisplatin, and 5-fluorouracil (DCF) therapy on degree of malignant esophageal stenosis. ( Inaki, N; Kinoshita, J; Moriyama, H; Nakamura, K; Okamoto, K; Saito, H; Shimada, M; Tsuji, T; Yamaguchi, T, 2023)
"We demonstrated in this study that dose escalation using IMRT in combination with platin-based chemotherapy as a definitive treatment for esophageal carcinoma is safe and results in higher loco-regional and control survival when compared to previously reported data."1.56Tolerance and efficacy of dose escalation using IMRT combined with chemotherapy for unresectable esophageal carcinoma: Long-term results of 51 patients. ( Carrère, N; Dalmasso, C; Guimbaud, R; Izar, F; Lusque, A; Modesto, A; Moyal, E; Rives, M; Vieillevigne, L, 2020)
"After 4 weeks, dysphagia scores improved by at least 1 point in 67% of patients in group 1 versus 93% in group 2 (p=0."1.40Chemotherapy versus self-expanding metal stent as primary treatment of severe dysphagia from unresectable oesophageal or gastro-oesophageal junction cancer. ( Archambeaud, I; Landi, B; Lepère, C; Lièvre, A; Mitry, E; Rougier, P; Touchefeu, Y, 2014)
"Strictures were associated with tumor location (tonsil vs base of tongue; p = ."1.37Factors associated with pharyngoesophageal stricture in patients treated with concurrent chemotherapy and radiation therapy for oropharyngeal squamous cell carcinoma. ( Best, SR; Blanco, RG; Califano, JA; Ha, PK; Levine, MA; Messing, BP; Murakami, P; Pai, SI; Saunders, JR; Thompson, R; Trachta, J; Ulmer, K; Walker, M; Zinreich, ES, 2011)
"The palliative effects on dysphagia of radiotherapy (RT) and chemotherapy (CT) were evaluated retrospectively and compared with the effect of the self-expanding stent, evaluated in the prospective study."1.29Palliation of dysphagia in patients with malignant esophageal strictures. Comparison of results of radiotherapy, chemotherapy and esophageal stent treatment. ( Albertsson, M; Cwikiel, M; Cwikiel, W, 1996)

Research

Studies (16)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's3 (18.75)18.2507
2000's3 (18.75)29.6817
2010's8 (50.00)24.3611
2020's2 (12.50)2.80

Authors

AuthorsStudies
Yamaguchi, T1
Okamoto, K1
Saito, H1
Shimada, M1
Tsuji, T1
Moriyama, H1
Kinoshita, J1
Nakamura, K3
Inaki, N1
Modesto, A1
Dalmasso, C1
Lusque, A1
Vieillevigne, L1
Izar, F1
Moyal, E1
Carrère, N1
Guimbaud, R1
Rives, M1
Okuno, T1
Wakabayashi, M1
Kato, K2
Shinoda, M2
Katayama, H1
Igaki, H2
Tsubosa, Y2
Kojima, T1
Okabe, H1
Kimura, Y1
Kawano, T1
Kosugi, S1
Toh, Y1
Kato, H1
Fukuda, H2
Ishikura, S1
Ando, N1
Kitagawa, Y2
Kobayashi, T1
Makino, T1
Yamasaki, M1
Tanaka, K1
Mori, M1
Doki, Y1
Touchefeu, Y1
Archambeaud, I1
Landi, B1
Lièvre, A1
Lepère, C1
Rougier, P1
Mitry, E1
Suh, YG1
Lee, IJ1
Koom, WS1
Cha, J1
Lee, JY1
Kim, SK1
Lee, CG1
Tsushima, T1
Mizusawa, J1
Sudo, K1
Honma, Y1
Best, SR1
Ha, PK1
Blanco, RG1
Saunders, JR1
Zinreich, ES1
Levine, MA1
Pai, SI1
Walker, M1
Trachta, J1
Ulmer, K1
Murakami, P1
Thompson, R1
Califano, JA1
Messing, BP1
Duman, L1
Büyükyavuz, BI1
Altuntas, I1
Gökcimen, A1
Ceyhan, L1
Darici, H1
Aylak, F1
Tomruk, O1
Clavier, JB1
Antoni, D1
Atlani, D1
Ben Abdelghani, M1
Schumacher, C1
Dufour, P1
Kurtz, JE1
Noel, G1
Abdel-Wahab, M1
Abitbol, A1
Lewin, A1
Troner, M1
Hamilton, K1
Markoe, A1
Guadagnolo, BA1
Haddad, RI1
Posner, MR1
Weeks, L1
Wirth, LJ1
Norris, CM1
Sullivan, CA1
Goguen, L1
Busse, PM1
Tishler, R1
Hanazono, K1
Natsugoe, S1
Okumura, H1
Matsumoto, M1
Oowaki, T1
Setoyama, T1
Hiraki, Y1
Arimura, K1
Nakamura, F1
Nakajo, M1
Aikou, T1
Burmeister, BH1
Denham, JW1
O'Brien, M1
Jamieson, GG1
Gill, PG1
Devitt, P1
Yeoh, E1
Hamilton, CS1
Ackland, SP1
Lamb, DS1
Cwikiel, M1
Cwikiel, W1
Albertsson, M1
Kuvshinov, IuP1
Poddubnyĭ, BK1
Aliev, VM1
Vasygova, NF1
Efimov, ON1
Khydyrov, KhB1
Saliuk, VA1

Clinical Trials (4)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
The Value of Sintilimab Consolidation Therapy After Definitive Concurrent Chemoradiotherapy for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma, an Open, Prospective, Single-arm Phase II Study[NCT04212598]Phase 240 participants (Anticipated)Interventional2020-08-03Recruiting
Quarterback 22: A Phase II Clinical Trial of Sequential Therapy and De-Intensified Chemoradiotherapy for Locally Advanced HPV Positive Oropharynx Cancer[NCT02945631]43 participants (Actual)Interventional2016-04-25Active, not recruiting
The Quarterback Trial: A Randomized Phase III Clinical Trial Comparing Reduced and Standard Radiation Therapy Doses for Locally Advanced HPV Positive Oropharynx Cancer[NCT01706939]Phase 323 participants (Actual)Interventional2012-09-01Active, not recruiting
A Prospective, Phase II Study of Percutaneous Endoscopic Gastrostomy Before Definitive Concurrent Chemoradiation Therapy in Patients With Esophageal Squamous Cell Carcinoma[NCT04380480]Phase 263 participants (Actual)Interventional2020-02-01Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Biomarkers Predictive of Failure

To determine biomarkers predictive of failure with either reduced or standard dose radiotherapy. (NCT01706939)
Timeframe: at 5 years

Interventionbiomarkers (Number)
Reduced Dose Radiation0
Standard Dose Radiation0

Change in MD Anderson Dysphagia Inventory (MDADI) From Baseline

MDADI is a questionnaire of 20 questions and contains a global subscale, and three other categories of questions (emotional, functional, and physical). The scores are summed and a mean score is calculated. This mean score was multiplied by 20 to obtain a score, with a range of 0 (extremely low functioning) to 100 (high functioning). Thus, a higher MDADI score represented better day-to-day functioning and better QOL. (NCT01706939)
Timeframe: Baseline and 5 years

Interventionscore on a scale (Mean)
Reduced Dose Radiation-8.12
Standard Dose Radiation-8.93

Change in Xerostomia Questionnaire (XQ)

XQ is a nine questions survey developed specifically for xerostomia symptoms. The scores are summed and a mean score is calculated on a scale of 0 (low xerostomia interference) to 10 (high xerostomia interference). A lower or negative score reflects a better quality of life compared to baseline. (NCT01706939)
Timeframe: Baseline and 5 years

Interventionscore on a scale (Mean)
Reduced Dose Radiation2.18
Standard Dose Radiation4.38

Number of Participants With Acute Toxicity of Chemoradiotherapy (CRT)

Number of participants with acute toxicity treated with reduced or standard dose CRT. (NCT01706939)
Timeframe: at 5 years

InterventionParticipants (Count of Participants)
Reduced Dose Radiation3
Standard Dose Radiation1

Number of Participants With Local-regional Control

Local-regional control (LRC) at 3 years in patients with advanced HPV related oropharynx cancer or unknown primary treated with reduced or standard dose radiation. (NCT01706939)
Timeframe: at 3 years

InterventionParticipants (Count of Participants)
Reduced Dose Radiation10
Standard Dose Radiation7

Number of Participants With Overall Survival at 5 Years

Overall Survival (OS) 5 years treated with reduced or standard dose CRT. (NCT01706939)
Timeframe: at 5 years

InterventionParticipants (Count of Participants)
Reduced Dose Radiation10
Standard Dose Radiation7

Change in European Organization for Research and Treatment of Cancer Questionnaire for Head and Neck (EORTC HN)

The EORTC Head and Neck module was specifically designed and validated for head and neck cancer patients. This 35-item questionnaire contains 7 symptom scales (pain, swallowing, senses, speech, social eating, social contact, and sexuality), 6 single-item scales (difficulties of teeth, mouth opening, dry mouth, sticky saliva, coughing, and feeling ill), and 5 items about the additional use of pain medicine, nutritional supplements, and feeding tube and changes in body weight. All items were transformed to scales from 0 to 100, and divided into respective sub-scores of global health (GHS), functional (FS), and symptom scale (SS). Subscales from 0-100. A high score on global health and functional scale represents a better level of functioning, whereas a high score on a symptom scale and head and neck module indicates more severe symptoms. (NCT01706939)
Timeframe: Baseline and 5 years

,
Interventionscore on a scale (Mean)
EORTC GHSEORTC FSEORTC SSEORTC HN
Reduced Dose Radiation5.955.14-3.91-2.80
Standard Dose Radiation-30.56-6.3314.978.97

Change in MD Anderson Symptom Inventory Symptom Inventory and Severity (MDASI-HN SI and SS)

"MD Anderson Symptom Inventory Symptom Inventory and Severity (MDASI-HN SI and SS) MDASI Head and Neck is a site-specific MDASI module which includes the core MDASI 13 symptom severity items (SS) and 6 symptom interference items (SI), alongside 9 items relevant to head and neck cancer. The scores are summed and a mean score is calculated on a scale of 0 (low severity or interference) to 10 (high severity or complete interference). In order to calculate the mean score, a majority of the subscale's items must have been completed.~A lower or negative score reflects a better quality of life compared to baseline." (NCT01706939)
Timeframe: Baseline and 5 years

,
Interventionscore on a scale (Mean)
MDASI-HN SIMDASI-HN SS
Reduced Dose Radiation0.640.52
Standard Dose Radiation1.561.48

Number of Participants With Progression Free Survival (PFS)

Progression free survival (PFS) at 5 years in patients with advanced HPV related oropharynx cancer, nasopharynx cancer or unknown primary treated with reduced or standard dose radiation. (NCT01706939)
Timeframe: at 3 and 5 years

,
InterventionParticipants (Count of Participants)
at 3 yearsat 5 years
Reduced Dose Radiation1010
Standard Dose Radiation77

Trials

5 trials available for fluorouracil and Esophageal Stenosis

ArticleYear
Esophageal stenosis and the Glasgow Prognostic Score as independent factors of poor prognosis for patients with locally advanced unresectable esophageal cancer treated with chemoradiotherapy (exploratory analysis of JCOG0303).
    International journal of clinical oncology, 2017, Volume: 22, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C-Reactive Protein; Carcinoma, Squamous

2017
Risk Factors for Esophageal Fistula Associated With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Cancer: A Supplementary Analysis of JCOG0303.
    Medicine, 2016, Volume: 95, Issue:20

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe

2016
Quality-of-life assessment after hyperfractionated radiation therapy and 5-fluorouracil, cisplatin, and paclitaxel (Taxol) in inoperable and/or unresectable head and neck squamous cell carcinoma.
    American journal of clinical oncology, 2005, Volume: 28, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su

2005
Organ preservation and treatment toxicity with induction chemotherapy followed by radiation therapy or chemoradiation for advanced laryngeal cancer.
    American journal of clinical oncology, 2005, Volume: 28, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell;

2005
Combined modality therapy for esophageal carcinoma: preliminary results from a large Australasian multicenter study.
    International journal of radiation oncology, biology, physics, 1995, Jul-15, Volume: 32, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aust

1995

Other Studies

11 other studies available for fluorouracil and Esophageal Stenosis

ArticleYear
Impact of preoperative docetaxel, cisplatin, and 5-fluorouracil (DCF) therapy on degree of malignant esophageal stenosis.
    BMC gastroenterology, 2023, Aug-18, Volume: 23, Issue:1

    Topics: Cisplatin; Constriction, Pathologic; Deglutition Disorders; Docetaxel; Esophageal Stenosis; Fluorour

2023
Tolerance and efficacy of dose escalation using IMRT combined with chemotherapy for unresectable esophageal carcinoma: Long-term results of 51 patients.
    Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 2020, Volume: 24, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

2020
Successful Stenting Followed by Surgery for Perforated Esophageal Cancer Due to Chemotherapy.
    The Annals of thoracic surgery, 2019, Volume: 108, Issue:6

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined

2019
Chemotherapy versus self-expanding metal stent as primary treatment of severe dysphagia from unresectable oesophageal or gastro-oesophageal junction cancer.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2014, Volume: 46, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

2014
High-dose versus standard-dose radiotherapy with concurrent chemotherapy in stages II-III esophageal cancer.
    Japanese journal of clinical oncology, 2014, Volume: 44, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; C

2014
Factors associated with pharyngoesophageal stricture in patients treated with concurrent chemotherapy and radiation therapy for oropharyngeal squamous cell carcinoma.
    Head & neck, 2011, Volume: 33, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali

2011
Factors associated with pharyngoesophageal stricture in patients treated with concurrent chemotherapy and radiation therapy for oropharyngeal squamous cell carcinoma.
    Head & neck, 2011, Volume: 33, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali

2011
Factors associated with pharyngoesophageal stricture in patients treated with concurrent chemotherapy and radiation therapy for oropharyngeal squamous cell carcinoma.
    Head & neck, 2011, Volume: 33, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali

2011
Factors associated with pharyngoesophageal stricture in patients treated with concurrent chemotherapy and radiation therapy for oropharyngeal squamous cell carcinoma.
    Head & neck, 2011, Volume: 33, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali

2011
The efficacy of single-dose 5-fluorouracil therapy in experimental caustic esophageal burn.
    Journal of pediatric surgery, 2011, Volume: 46, Issue:10

    Topics: Animals; Burns, Chemical; Caustics; Cell Differentiation; Cell Division; Cicatrix; Drug Evaluation,

2011
Baseline nutritional status is prognostic factor after definitive radiochemotherapy for esophageal cancer.
    Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2014, Volume: 27, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

2014
[An effective treatment by chemoradiation therapy after stent insertion for advanced esophageal cancer with esophago-pulmonary fistula--report of a case].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali

2007
Palliation of dysphagia in patients with malignant esophageal strictures. Comparison of results of radiotherapy, chemotherapy and esophageal stent treatment.
    Acta oncologica (Stockholm, Sweden), 1996, Volume: 35, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen

1996
[Endoscopic laser recanalization in the chemo- and radiotherapy of stenosing cancer of the esophagus].
    Sovetskaia meditsina, 1990, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Esophageal Neoplasms; Esophageal

1990